4-fluoro-N-(4-hydroxyphenyl)benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-fluoro-N-(4-hydroxyphenyl)benzamide
• 化学式: C₁₃H₁₀FNO₂
• mdl: MFCD00442114
• 分子量: 231.226
• InChiKey: BIEXWTLSOKJVPK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-((1R,2R,3R)-3-hydroxy-2-((E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)heptanoic acid 、 4-fluoro-N-(4-hydroxyphenyl)benzamide 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 14.05h， 以70%的产率得到4-(4-fluorobenzamido)phenyl 7-((1R,2R,3R)-3-hydroxy-2-((E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)heptanoate
  参考文献：
  名称：

  PROSTAGLANDIN ANALOGS AND USES THEREOF

  摘要：

  本发明涉及一种药物组合物，用于预防或治疗与Nurr1相关的疾病、紊乱或状况，其中包括作为活性成分的前列腺素类似物或其药学上可接受的盐，该化合物具有良好的诱导Nurr1的效果，因此，可用作预防或治疗与Nurr1相关的疾病、紊乱或状况的药物组合物，特别是癌症、自身免疫性疾病如类风湿关节炎、精神分裂症、躁郁症以及神经退行性疾病如阿尔茨海默病或帕金森病。

  公开号：

  US20210139435A1
• 作为产物：
  描述：

  对氟碘苯 、 一氧化碳 、 对氨基苯酚 在 palladium diacetate 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 1,3-bis(diisobutylphosphino)propane 作用下， 以 乙腈 为溶剂， 100.0 ℃ 、1.38 MPa 条件下， 反应 15.0h， 以85%的产率得到4-fluoro-N-(4-hydroxyphenyl)benzamide
  参考文献：
  名称：

  Pd-Catalyzed Chemoselective Carbonylation of Aminophenols with Iodoarenes: Alkoxycarbonylation vs Aminocarbonylation

  摘要：

  Palladium-catalyzed chemoselective carbonylation of aminophenols with iodoarenes was realized by changing ligand and base. 3- or 4-Aminophenols afforded esters in high yields and selectivities using 1,3-bis(diphenylphosphino)propane as the ligand and K2CO3 as the base, and gave amides in high yields and selectivities using 1,3-bis(diisobutylphosphino)propane as the ligand and DBU as the base. 2-Aminophenol only gave amides in high yields under both conditions.

  DOI：

  10.1021/ja508588b

文献信息

• Modulators of peroxisome proliferator activated receptors
  申请人：Brooks Alisa Dawn

  公开号：US20050020684A1

  公开（公告）日：2005-01-27

  Disclosed is a compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aromatic group. Q is a covalent bond, —CH 2 — or —CH 2 CH 2 —; W is a substituted or unsubstituted alkylene or a substituted or unsubstituted heteroalkylene linking group from two to ten atoms in length, preferably from two to seven atoms in length. Phenyl Ring A is optionally substituted with up to four substituents in addition to R 1 and W, R 2 is (CH 2 ) n —CH(OR 2 )—(CH 2 ) n E, —(CH)═C(OR 2 )—(CH 2 ) n E, —(CH 2 ) n —CH(Y)—(CH 2 ) m E or (CH)═C(Y)(CH 2 ) m E; wherein E is COOR 3 , C 1 -C 3 alkylnitrile, carboxamide, sulfonamide, acylsulfonamide or tetrazole and wherein sulfonamide, acylsulfonamide and tetrazole are optionally substituted with one or more substituents independently selected from: C 1 -C 6 alkyl, haloalkyl and aryl-C o - 4 -alkyl; R 2 is H, an aliphatic group, a substituted aliphatic group, haloalkyl, an aromatic group, a substituted aromatic group, —COR 4 , —COOR 4 , —CONR 5 R 6 , —C(S)R 4 , —C(S)OR 4 or C(S)NR 5 R 6 , R 3 is H, an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. Y is O—, CH 2 —, CH 2 CH 2 — or CH═CH— and is bonded to a carbon atom in Phenyl Ring A that is ortho to R 1 . R 4 -R 6 are independently H, an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. n and m are independently 0, 1 or 2.

  本发明公开了一种由结构式（I）表示的化合物：其中Ar是取代或未取代的芳香基团。Q是共价键，-CH2-或-CH2CH2-; W是取代或未取代的烷基或取代或未取代的异烷基连接基，长度为两到十个原子，优选长度为两到七个原子。苯环A可选地与R1和W以外的最多四个取代基取代，R2是（CH2）n-CH（OR2）-（CH2）nE，-（CH）=C（OR2）-（CH2）nE，-（CH2）n-CH（Y）-（CH2）mE或（CH）=C（Y）（CH2）mE;其中E是COOR3，C1-C3烷基腈，羧酰胺，磺酰胺，酰基磺酰胺或四唑，磺酰胺，酰基磺酰胺和四唑可选地与一个或多个取代基取代，独立地选自：C1-C6烷基，卤代烷基和芳基-Co-4-烷基; R2是H，脂肪基，取代脂肪基，卤代烷基，芳基，取代芳基，-COR4，-COOR4，-CONR5R6，-C（S）R4，-C（S）OR4或C（S）NR5R6，R3是H，脂肪基，取代脂肪基，芳基或取代芳基。Y是O-，CH2-，CH2CH2-或CH═CH-，并与Phenyl环A中与R1相邻的碳原子键合。R4-R6独立地是H，脂肪基，取代脂肪基，芳基或取代芳基。n和m独立地为0、1或2。
• Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof
  申请人：Tozawa Takashi

  公开号：US20080167307A1

  公开（公告）日：2008-07-10

  According to the present invention, a compound represented by the following formula (I) having a superior PPAR α agonist action and concurrently showing a hypolipidemic action can be provided, and further, a compound useful as a synthetic intermediate for the compound can be provided.

  根据本发明，可以提供一种具有卓越的PPARα激动剂作用并同时显示降脂作用的化合物，该化合物表示为以下公式（I），并且还可以提供一种用作该化合物的合成中间体的化合物。
• CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF
  申请人：Mitsubishi Pharma Corporation

  公开号：EP1816128A1

  公开（公告）日：2007-08-08

  According to the present invention, a compound represented by the following formula (I) having a superior PPARα, agonist action and concurrently showing a hypolipidemic action can be provided, and further, a compound useful as a synthetic intermediate for the compound can be provided.

  根据本发明，可以提供一种由下式（I）表示的化合物，该化合物具有优异的 PPARα 激动剂作用，同时还具有降血脂作用，此外，还可以提供一种可用作该化合物合成中间体的化合物。
• MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS
  申请人：ELI LILLY AND COMPANY

  公开号：EP1392637A2

  公开（公告）日：2004-03-03
• US7192982B2
  申请人：——

  公开号：US7192982B2

  公开（公告）日：2007-03-20